The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

Researchers evaluated the efficacy of low-dosage fluvoxamine (50 mg two times a day) over 10 days in the management of mild and moderate-SARS-CoV-2 infections in the US.